gprc5d/cd3 bites
mAbexperimentalBi-specific
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Aug 10, 2025 (NCT07106710)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
CD3E activator
GPRC5D inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07106684 | Phase 2 | Aug 10, 2025 | China Academy of Chinese Medical Sciences |
| NCT07106736 | Phase 2 | Aug 10, 2025 | China Academy of Chinese Medical Sciences |
| NCT07106710 | Phase 2 | Aug 10, 2025 | China Academy of Chinese Medical Sciences |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| China Academy of Chinese Medical Sciences | Academic/Hospital | 3 | 3 | 1 | 2025 |
1 organizations
Page 1 / 1